Cancer Prevention Pharmaceuticals has submitted a New Drug Application (NDA) to the FDA seeking accelerated approval for CPP 1X/sul for treatment of adults with familial adenomatous polyposis (FAP).
The German guideline for the treatment of psoriasis vulgaris was updated using GRADE methodology. The guideline is based on a systematic literature review completed on December 1, 2016, and on a formal consensus and approval process.
In addition to the interventions discussed in the update, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) approved apremilast and secukinumab as new treatment options for psoriasis.
The FDA has approved the New Drug Application for Fabior (tazarotene) Foam, 0.1%, from Allergan, for the treatment of Acne...
Sol-Gel Technologies, Ltd. announced that the FDA has approved its first proprietary drug product, Twyneo (tretinoin/benzoyl peroxide) cream, 0.1%/3%, indicated for the treatment of acne vulgaris in adults and pediatric patients nine years of age and older.
This is an executive summary of all consented recommendations of the European Psoriasis Guidelines – Update 2015. The long version of this guideline is available online as supplementary file. A detailed...
In recognition of the impact of psoriasis on patients the World Health Assembly (WHA) in May 2014 supported including psoriasis into the group of non-communicable diseases.
Roche announced that the European Commission has approved MabThera (rituximab) for the treatment of adults with moderate to severe pemphigus...
Stiefel/GSK has announced the start of a Phase III study to evaluate the efficacy and safety of subcutaneous ofatumumab (Arzerra)...
Genentech/Roche announced that the FDA has accepted the company�s Supplemental Biologics License Application (sBLA) and granted Priority Review for the...